CSPC PHARMA: SYH2070 injection (double-stranded small interfering RNA drug) has received clinical trial approval in the United States
I'm PortAI, I can summarize articles.
CSPC PHARMA announced that its self-developed SYH2070 injection has been approved by the U.S. FDA for clinical trials. This drug is a double-stranded small interfering RNA designed to lower ANGPTL3 levels by targeting angiopoietin-like protein 3, suitable for hypertriglyceridemia or mixed hyperlipidemia. Preclinical studies have shown that it outperforms similar products in terms of drug activity and persistence, demonstrating high clinical development value
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments